They are Semaglutide (Wegovy), which is a similar medication to Ozempic, which is mainly used in diabetic patients, as well as Tirzepatide (Zepbound) and Liraglutide (Saxenda)
For heart failure or chronic kidney disease, the American Diabetes Association generally recommends SGLT2 inhibitors as first-line agents, with GLP-1 receptor agonists considered for their benefits on atherosclerotic cardiovascular disease, glycemic control, and weight management, or when SGLT2 inhibitors are not appropriate
These guidelines apply whether youre using Ozempic, Wegovy, Zepbound, or Mounjaro
Semaglutide produces substantial weight loss at $199 monthly in compounded form
This discipline eliminates the most common source of accidental room temperature exposure
Our Berberine patches are infused with a unique blend of ingredients that work together to curb your appetite and reduce snacking